Clinical trials
Hyperbilirubinemia, Neonatal trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
12 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2018 | 3 |
| 2019 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 7 |
| Withdrawn | 2 |
| No longer available | 1 |
| Terminated | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | 3 |
| HonorHealth Research Institute | 1 |
| Massachusetts General Hospital | 1 |
| NICHD Neonatal Research Network | 1 |
| Stanford University | 1 |
| State University of New York - Upstate Medical University | 1 |
| The University of Texas Health Science Center, Houston | 1 |
| University of California, San Francisco | 1 |
| University of Rochester | 1 |
| William Marsh Rice University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hyperbilirubinemia, Neonatal | 12 |
| Jaundice, Neonatal | 8 |
| Hyperbilirubinemia | 3 |
| Jaundice | 3 |
| Hemolysis | 2 |
| Premature Birth | 2 |
| Disease | 1 |
| Erythroblastosis, Fetal | 1 |
| Glucosephosphate Dehydrogenase Deficiency | 1 |
| Infant, Newborn, Diseases | 1 |
Trials
Showing 1 to 12 of 12. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.